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Abstract
Due to the sensitivity of location, brain cancer is one of the most difficult and deadly known cancers. There are various forms of
cancer in the brain with many shared characteristics as well as unique manifestations in each. While cancers originating in the
central nervous system present in several ways, the most common forms are high grade gliomas generally, and glioblastoma or
anaplastic astrocytomas specifically. With the advent of technology, researchers have been able to propose and refine extensive
profiles of these relentless tumors, enabling greater and more successful treatment profiles to be developed. Where treatments
used to consist primarily of chemotherapy and surgery, research has enabled the development of immunotherapy and gene
therapy techniques as well as alternative treatments to take on the caustic disease.
Introduction
The foremost distinction of brain tumors is between primary;
those that originated within the brain itself, and secondary; those
that developed beyond the blood brain barrier and migrated to
the brain under metastatic conditions. Secondary tumors account for the majority of all brain cancers and approximately
50% of these tumors metastasize from lung cancers (Gallego,
2015). According to the 2014 World Cancer Report, patients
diagnosed with glioblastomas were measured to have a median
survival time of 12-15 months post diagnosis with fewer than
5% of patients living beyond 3 years (Patchell, 2003).Under the
World Health Organization’s grading protocol for central nervous system (CNS) cancers, glioblastomas (GBM) are a grade
IV glioma (Bleeker, et al., 2011). This is the most common form
of primary brain tumor and the most fatal found in humans,
accounting for 15% of all intracranial neoplasms (Bleeker, et al.,
2011;Young, et al., 2015).The average age at diagnosis is 64 years
old and the approximate annual incidence of GBM per 100,000
population is 3.19 cases, making an understanding of the disease and its treatment of paramount importance (Ostrom et
al., 2017). GBMs develop rapidly de novo in astrocytes, starshaped neuroglial cells suspected to play a role in blood brain
barrier maintenance and neurotransmitter management (Kolb
& Whishaw, 2009). This swift development occurs without any
previous primary or lower grade lesion development that may
indicate or preclude the GBM onset, making early diagnosis and
adequate treatment more difficult.
Since 2005, the first-line standard of care has been established as surgery followed by chemotherapy, most often with
temozolomide (TMZ), and radiotherapy. Despite the established
longevity of this standard, its efficacy is highly questionable and
there is still recurrence in the majority of cases (Patchell, 2003).
To complicate matters further, there is no second-line standard
of care for glioblastomas and recurrence is consistently fatal
(Roy, et al., 2015).

Discussion: Difficulties with Conventional
Treatments
One of the significant factors contributing to the aggressive
character of GBMs is their infiltrative nature. Astrocytes have
extensive networks of processes forming from their cell bodies,
creating an intricately branched structure extending throughout the nervous system. Where some cancers merely invade
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their host tissue, the cells of grade IV astrocytomas penetrate
their host with protrusions. These processes weave a complex
margin with host tissue that blurs the border between invasive
and host cells. This makes complete surgical resection nearly
impossible as practitioners are unable to differentiate between,
and separate, the healthy and malignant tissue. As a result, recurrence is extremely high in GBMs and alternative treatments
must often be considered post-surgery when complete resection is not achieved (Patchell, 2003).
Beyond the inability to properly remove gliomas, the benefit
of surgery is questionable. In a study of recurrent brain tumors,
researchers found no significant benefit to a second resection,
though a first resection did confer an increased overall survival
(Suchorska et al., 2015). Nonetheless, the nature of the neurosurgical procedure lends itself to various complications. Along with
the wound and postsurgical medical complications, brain surgery
runs the risk of systemic and cortical injuries, damaging physical
and mental health with the most common risk of neurological
impairment (Jackson, et al., 2016). Research also found that the
acquisition of motor and language deficits post-surgery is linked
to decreased survival rates compared to patients without surgical
brain damage (McGirt et al., 2009). The results of these studies
indicate that the benefit of surgery is questionable.
Chemotherapy treatments generally follow the attempted resection procedures but have limited success due to the impermeability of the blood brain barrier to foreign chemicals (Deeken &
Loscher, 2007).TMZ is a common chemotherapy drug for gliomas
and has demonstrated mild success against GBM and anaplastic
astrocytoma but its overall effectiveness is slim and is accompanied by a cocktail of undesirable side effects (Friedman, et al,
2000).The established first-line standard of care is precarious and
insufficient. As a result, research has turned to alternative methods by which to treat and manage this deadly.

Genetic Analysis
In order to purposefully theorize and discuss possible solutions
and treatments, GBM manifestation must first be understood.
Occurring primarily in older patients, GBM progresses quickly
and with low survival rates. A minority of cases have been seen in
younger patients with a history of epilepsy connected to progressive low-grade gliomas (Ostrom et al., 2015). To address the lack
of understanding, research continues to look for commonalities
in tumor onset.As genomic instability is an enabling characteristic
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of cancer, efforts have been made in the field to source a primary effector with genetic basis. As of yet, there is only one confirmed molecular predictive factor for GBM - methylation of the
O6-methylguanine-DNA methyltransferase (MGMT) promoter
(Bleeker, et al, 2011). The relative dearth of information on the
molecular basis for GBM requires additional research.
Whole-genome single nucleotide polymorphism (SNP)-based
array analysis of gene expression in GBM patients has indicated
several genetic changes that shed some light on the nature of
the illness. Notably, loss of heterozygosity frequently occurs on
the 17p gene, which contains the tumor protein 53 (p53) (The
Cancer Genome Atlas (TCGA), Research Network, 2008). Loss
of heterozygosity refers to the deletion of a chromosome portion with the corresponding homologous segment being duplicated to compensate for the loss of gene neutrality (Bleeker, et
al, 2011).The significance of this mutation is reflected in the loss
of genetic code for p53. p53 encodes a nuclear phosphoprotein involved in regulation of cell proliferation. In other words,
wild type p53 is a tumor suppressor gene. Mutations in p53 not
only cause loss of tumor suppression, they can activate p53 to
an oncogene in a negatively dominant fashion implicating these
mutations in a number of cancers (Finlay, et al., 1989). Further,
loss of heterozygosity of chromosome 10q is associated with
poor rates of survival and is the most common genetic alteration found in primary and secondary GBM’s.This chromosome
contains various tumor suppression codes, most notably the
region containing ANXA7, an epidermal growth factor receptor (EGFR) inhibitor, and deletions contribute to a proliferation
of cell growth; a distinguishing behavior of cancerous tumors
(Yadav et al., 2009).
Additional research focuses on genetic amplifications associated with GBM. Specifically, amplification of the gene for EGFR
on chromosome 7 has been shown to be a consistent characteristic in glioblastomas (Finlay, et al, 1989; Bleeker, et al, 2011).
Focal amplifications (amplifications containing a small concentration of genes) correlate with overexpression or mutation
of EGFR, leading to subsequent activation of the PI3K/AKT
pathway, another indicator of poor prognosis (Beroukhim et al.,
2007; Phillips et al., 2006). General amplification of entire chromosomes, specifically chromosome 7, has shown correlation
with the activation of the Met axis, a codependent cycle with
Hepatocyte Growth Factor (HGF) which furthers the occurrence of cell proliferation (The Cancer Genome Atlas (TCGA),
Research Network, 2008).
Another genetic component considers IDH1 mutations.
The IDH1 gene codes for isocitrate dehydrogenase 1, a critical
component of the citric acid cycle, catalyzing the conversion of
isocitrate to α-ketoglutarate. Mutations of this gene have been
discovered in 12% of glioblastomas (Watanabe, et al., 2008).
Mutations of this enzyme do not appear to cause loss of function, rather, cancer-associated IDH1 mutations alter the reaction

of the enzyme, enabling it to catalyze the NADPH-dependent
reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG).
As many humans have a reduced capacity to dispose of 2HG
in an efficient manner, overaccumulation of the metabolite has
been implicated in the formation of malignant brain tumors
(Dang et al., 2009). 2HG also has a penchant to activate NF-κB,
a prominent protein complex that controls cytokine production, cell survival, and DNA transcription, implicating it in many
cancers, including various leukemias (Chen et al., 2016).
Ultimately, the strongest evidence of a genetic aspect to GBM
is that of the MGMT promoter.While TMZ treatment in general
has shown some benefit, much of its effectiveness is diminished
by this molecular occurrence. TMZ acts by modifying the O6position in guanines. This translates to DNA lesions leading to
DNA cross-links preventing cell replication. MGMT can remove
the alkyl groups and contribute to TMZ resistance but not
when methylated. Because about 50% of patients exhibit MGMT
methylation, the effectiveness of TMZ is considerably lessened
in approximately half of all cases (Bleeker, et al., 2011). Research
is being done particularly in this area to better understand the
environment surrounding methylation and prospectively harnessing the power of methylation to increase TMZ effectiveness
(Lee et al., 2018).
Additional aberrations in genetic behavior exist in GBM with
varying degrees of frequency. With more tools becoming available, it is apparent that the picture of GBM is not clear and
further genetic research is required. Nonetheless, these tools
enable researchers to identify the most prevalent deviations
from typical behavior. For example, many alterations occur
within three primary pathways; the p53, RB, and PI3K/AKT
pathways, and appear to occur in a mutually exclusive fashion
(The Cancer Genome Atlas (TCGA), Research Network, 2008).
This defines a narrower scope of application, hopefully resulting
in the development of rational therapeutic techniques and drug
design. These genomic approaches may ultimately contribute to
more individualized therapies for greater patient longevity.

Immune Evasion and Immunotherapy
In addition to the complications involved with gene aberrations
in malignant gliomas, the impressive rate at which GBMs evade
natural immune response opens another point of study for
prospective treatments. Avoidance of the immune system was
added as a defining characteristic of cancer in 2011 and an examination of the natural immune response has helped develop
vaccinations and treatments for various diseases (Hanahan &
Weinberg, 2011). Nonetheless, the ability of tumors to dodge
these receptors requires a better understanding, specifically in
the brain. In line with original theories, the CNS is immunologically privileged. Unfortunately, it is not quite as privileged
as once suspected. While early theories assumed this privilege
was a result of isolation of the brain by the blood brain barrier,
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newer research refutes this. Peripheral immune cells do in fact
cross the barrier, but CNS neurons and glia regulate immune
responses in a different fashion than other cells (Carson, et
al., 2006). Researchers have demonstrated this deviance from
the standard immune system using experimental foreign grafts
to rabbit brain. These grafts were rejected at a much slower
rate than grafts to less unique locations (Medawar, 1948). An
additional indication of CNS immune system inadequacy is the
immune response of the brain in multiple sclerosis patients. The
immune system of affected individuals appears to contribute
directly to the proliferation of the disease rather than fighting it
(Hemmer, et al., 2015). Despite these deficiencies, analysis suggests proper manipulation of the immune system can assist in
the fight against brain cancers, achieved through understanding
the mechanism by which tumors evade it.
ICT-107 is a multiple-antigen-pulsed dendritic cell vaccine
containing multiple tumor-associated antigens (HER2, TRP-2,
gp100, MAGE-1, IL13Rα2, and AIM-2) known to interact with
glioma stem cells. These antigens may be ideal for vaccination
as their introduction to the dendritic cell tumor environment
stimulates T-cells to generate glioblastoma specific cytotoxicity
(Huang et al., 2017). This immunotherapy was the first such trial
to reflect significant results in terms of overall, progression-free
survival in newly diagnosed GBM (McGranahan, et al., 2017).
A phase III trial is awaiting additional funds to further investigate the effectiveness of this vaccine (Phuphanich et al., 2012).
Another vaccine in phase II trials is Gliovac. This vaccine utilizes
autologous antigens from the patient subjects combined with
allogeneic antigens (antigens with a dissimilar genetic makeup
from that of the patient) derived from other GBM patients.
Beyond using tumor lysate, the Gliovac vaccine is designed
similarly to ICT-107 to encourage the development of cytotoxic T-cells to enhance the struggling immunological response
(Schijns,Virgil E J C et al., 2015). Further studies examine the link
between the CTLA-4 receptor, a constitutively active receptor
on the Treg gene, and its downregulation of the immunologic
response in active T cells (Leach, et al., 1996). By blocking CTLA4, researchers have seen considerable success with enhancing
antitumor immunity, rejecting both artificially introduced and
pre-established tumors. The rapid growth of immunotherapeutic treatments stresses the importance of a more comprehensive understanding of the immune system and its reactions
to foreign in vivo developments. More specific information on
marker antibodies will go a long way in furthering treatments,
not only for GBM but also for other immuno-evasive diseases.

Treatment with Infection
A seemingly counterproductive method of treatment has been
considered to address incomplete resection of glioblastoma
tumors. While the actual number of surgical site infections
after malignant brain tumor resection is not well established,
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data indicates the rate to be about 3.4% (Uzuka et al., 2017). A
speculative theory supported with anecdotal evidence presented the idea that patients who developed postoperative bacterial
infections and survived had a radically increased overall survival.
A study reported four cases of patients with surgical site infections living well beyond the expected range of survival for
glioblastoma (Bowles, et al., 1999). This theory has been subjected to several trials and though not statistically significant, results showed that many infected patients live longer on average
though reverse logic may be cloud results. Infection may correlate with increased life span because patients that live longer
are more likely to develop an infection, not because infection
lengthens survival (De Bonis et al., 2011).

Antiangiogenic Treatments
Antiangiogenic treatments have shown a lot of promise in cancers management and particularly in that of GBM as second-line
treatments. The rationale for antiangiogenics is strong; as cancers
are highly vascular, preventing the growth of blood vessels to supply the tumor should help deplete tumor resources and severely
retard malignancy. Tumors are known to exploit the body’s nutrient and oxygen supplies and require enhanced networks of blood
and lymphatic vessels to facilitate this resource abuse (Nishida,
et al., 2006). Vascular endothelial growth factor (VEGF) is a signaling protein that stimulates the creation of blood vessels and
has received increased attention as an indicator of oncogenesis
(Pavlova & Thompson, 2016). To address this, researchers developed Bevacizumab, a monoclonal antibody that counters the
effects of VEGF and has been approved for trials in the United
States for some time. Dosed intravenously, Bevacizumab has been
used independently as a monotherapy and in pairs or groups of
antiangiogenics for a multi therapeutic approach in various cancer
types. In early trials, a statistically significant number of patients
demonstrated an improvement in overall survival, but randomized phase III trials have been unable to demonstrate an appreciable improvement in overall survival required to move this form of
therapy forward (Bleeker, et al., 2011).

Retroviral Delivery
A promising treatment technique addresses issues with alternative treatments. Retroviral replicating viruses (RRVs), are a novel
way of treatment delivery and contain a wide variety of unique
characteristics that allow for highly specific gene transfer in an
efficient manner. Pharmaceutical companies are combining many
of the above therapies into a single, comprehensive treatment
method for recurrent high-grade gliomas with the goal of extending these concepts to further treatments.
Retroviruses are positive-sense RNA viruses. These obligate
parasites cannot reproduce or complete their life cycle without
a host cell. Once within a host, these viruses use the enzyme
reverse transcriptase to produce DNA from the viral RNA
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sequences. This DNA strand is then incorporated into the host
cell genome with an integrase enzyme. By transferring it’s genetic data into the host, the virus ensures it will be reproduced
when the host reproduces. The applications of these viruses
can allow scientists to produce desired proteins and genetic
products for treatment purposes. These viruses confer many
advantages to the treatment of cancers and in particular, of
glioblastoma. One such benefit of RRVs is the selective acceptance within cells. It has previously been established that tumors
exhibit a distinct loss of immunity and that a central aspect of
cancer development is the evasion of the immune system. Cell
populations naturally assess tissue to prevent proliferative, uncontrolled growth, and cancers evolve to avoid the anti-tumor
response. This evolution evades immune checkpoints and regulators but also enables immunoediting, the process by which
cancers read, react, and adapt to immune processes. By disabling
the anti-tumor response, cancer cells can replicate continuously
unchecked (Butt, et al., 2004). The lack of immunity that permits cancers to exist also creates an opportunity for medical
intervention. RRVs are generally recognized by healthy cells and
dealt with accordingly by the normal immune system, but the
reduced defense mechanism of cancer cells allows the RRV to
incorporate genetic components into the cancer gene pool.This
selective acceptance safeguards healthy tissue while priming
cancer cells. Another key feature of RRVs is the ability to spread
non-lytically and without an exceptional inflammatory response.
Gene products are not produced until the virus is activated
and this avoids an inflammatory response from the innate immune system (which is not heavily compromised). Coupled
with a nonlytic retroviral infection, this delivery system enables
researchers to target specifically cancerous or immunocompromised cells (Logg, et al., 2012).
The Tocagen therapy relies on an engineered retrovirus known
as Toca 511 (vocimagene amiretrorepvec) for delivery. Toca 511
is a murine leukemia virus that infects dividing cells, preferentially
integrating into cells that are immune-deficient — in this case
GBM cells. In addition, the retrovirus has no trouble crossing the
blood brain barrier, an issue that arises with other treatments.
The virus contains the genetic code for an altered cytosine
deaminase (CD), a protein enzyme that catalyzes the reaction
converting cytosine residues to uracil (Ostertag et al., 2011). In
trials, after several cycles of RRV treatment, researchers found
a high concentration of CD present in tumor cells, but none or
insignificant levels expressed in quiescent cells. The retrovirus
delivery method efficiently targets tumor cells and integrates its
genetic contents into the DNA of the host cell without affecting
the genetic integrity of healthy cells in the body.
While the success of the genetic transfer is significant, the
expression of optimized CD within tumor cells is of little consequence. Further action is required to have an impact on cancerous cells. 5-fluorocytosine (5-FC) is subsequently administered

as a prodrug, a drug in an inactive form. Despite widespread uptake of 5-FC by the majority of cell types, this inactivity prevents
any notable response from quiescent or typical cells. However,
in the Toca-511 pretreated tumor cells, 5-FC is converted by
CD to 5-fluorouracil (5-FU), a potent antineoplastic cancer
drug used as the drug of choice for colorectal, esophageal, gastric, and many other cancers. While the precise mechanism of
5-FU is unknown, it is suspected to interfere with DNA synthesis, protein synthesis, and RNA processing (Pinedo & Peters,
1988). Collectively, these contribute to an incompatible state
for the tumor cell leading to apoptosis and subsequent removal
by the immune system. Furthermore, 5-FU has also been shown
to destroy myeloid-derived suppressor cells. These cells help
evade the immune system and elimination of these suppressor
cells allows the patient’s natural immunity to assist in tumor
destruction (Cloughesy et al., 2016). An additional advantage
of the engineered 5-FU produced in Toca-511 allows the active
drug to diffuse through the cell membrane, giving the potential
to have therapeutic effects reaching beyond the cytosol of the
parent cell (Hemmer, et al., 2015). There is strong evidence to
suggest this phenomenon, called the bystander effect, occurred
in preliminary trials and it resulted in an improved overall survival rate as well as an improved recurrence free outcome. The
Tocagen drugs are undergoing clinical trials but the progress
they signify in science is considerable and opens the door to a
proliferation of improved treatment techniques.

Multi-Therapy
The multi hit model of cancer, also known as the Knudson hypothesis, is the theory originally proposed in 1953 hypothesizing
a stepwise component to oncogenesis.The theory suggests that
cancer onset is not the result of a single mutation, rather the
outcome of many mutations, creating conditions for the perfect
storm that is cancer (Nordling, 1953). Knudson’s hypothesis
has greater validity after “Hallmarks of Cancer” was published
by Weinberg and Hanahan (Hanahan & Weinberg, 2000). The
hallmarks reiterate the idea that cancer is multi-faceted and
more complex than a single aberration in physiology and development. The theory gives rise to an alternate approach to
treatments; if the disease is multifaceted, then so must be the
treatment plan. Various treatment proposals utilize this theory for multi-hit therapy. Some antiangiogenic treatments are
being applied in conjunction with others for a comprehensive
approach. Several attempts have been made, or are now in trials,
that couple effective treatments like that of TMZ with newer
medications to enhance their effectiveness. In concurrence with
TMZ, patients have been tested with a wide variety of pharmaceutical cocktails, including gefitinib and erlotinib, a pair of
EGFR inhibitors (Bleeker, et al., 2011). Patients have also been
treated with radiotherapy and Gliadel wafers. These wafers
are intracranial implants containing carmustine, a nitrosourea
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alkylating agent, and give a steady treatment of chemotherapy
to their host after being inserted into the brain (van den Bent
et al., 2008). Direct insertion prevents the need to circumvent
the blood brain barrier and offers a continuous administration
of the drug for the duration of the treatment. As a nitrosourea,
carmustine alkylates DNA strands, preventing normal gene
expression in cancer cells and dampening tumor development.
Further, contrary to previous research, resistance to a single alkylating agent does not predict resistance to alternate alkylating
agents, allowing for a multi-agent approach to prevent cancer
gene expression (Schabel, 1976).
The development of chimeric antigen receptor T-cell therapy
(CAR-T) builds on the success of above-mentioned treatments
such as retroviral genetic manipulation and immune system
enhancement. This technique utilizes engineered T-cells to recognize specific markers in cancer cells and induce apoptosis.
One lab at the Memorial Sloan Kettering Cancer Center focused on B cell acute lymphoblastic leukemia and is examining options to extend this therapy to gliomas. In the leukemia
study, patients with relapsed B cell acute lymphoblastic leukemia had T-cells isolated from plasma and treated with a vector.
The vector programmed T-cells to produce chimeric antigen
receptor, a receptor that can be engineered to enable the T
cells to recognize specific proteins found in cancers (CD19 in
this case) (Brentjens et al., 2013). One particular advantage of
CAR-T therapy is the use of the patient’s own immune cells.
Using autologous material decreases the incidence of rejection
or other complications that frequently occur with the introduction of foreign cells (Almasbak, et al., 2016). CAR-T therapy
has demonstrated high rates of success with above an 88% long
term survival rate and is being evaluated for expansion to a
greater variety of cancers, including high- and low-grade glioma
(Wilkins, Keeler, & Flotte, 2017).
The range of ideas employed with multi-hit therapies and
techniques takes advantage of the advances made in genetic
and molecular research. Introducing therapies that make use
of immunotherapy and genetic recombination, or that address
multiple facets of angiogenesis are particularly useful in tackling
the multidimensional aspects of cancer. Combination treatments allow scientists to develop a more comprehensive blend
that can address the particular deficiencies associated with each
individual medication and enable an extensive treatment plan
for the greatest chances of survival.

Conclusion
Glioblastoma multiforme is a high-grade malignancy with a poor
prognosis. While additional preventative research is required to
improve diagnostic methods and screening, management methods are under rapid development to improve not only survival
but also quality of life. A greater focus on intermolecular functioning within GBM helps provide a better understanding of how
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to effectively diagnose and recognize the cancer. Additionally,
such information allows the introduction of periodic screening
in higher risk individuals as determined by these advances. By
analyzing intermolecular pathways such as kinase receptors and
genetic modifications, researchers can develop steps or procedures to counter the cancer. This basic research extends itself
heavily to the applied sector and allows for the creation of therapies and treatments that respond to the characteristics and actions unique to this disease and the complexities of its location.
Many treatments have already been proposed in an attempt
to contain the rapid tumor proliferation associated with glioblastomas. With the knowledge gained from the success and
failures of these treatments, adjusted multi-therapy approaches
and novel replacement techniques have been developed. From
genetics and immunological studies to bacterial and retroviral
infections, these alternatives offer increased variability and possibility for patients. Despite the grim prognosis that typically
accompanies the diagnosis of GBM, there is the potential for the
cancer to no longer be as debilitating as it currently is or once
was. Particularly through immunotherapy and gene therapy, as
well as the use of antiangiogenics and nitrosourea alkylating
agents, GBM can soon be combatted beyond the standard of
surgical resection and chemotherapy.
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